FDA approves new cystic fibrosis therapy

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).

Cancer researcher: “We can do better and reduce suffering”

Lund University researcher Catharina Hagerling is developing innovative methods to understand metastatic cancer, aiming to create more targeted treatments for p...

Läkemedel slipper Trumps tullar – branschens reaktioner

USA inför tullar på minst 10 procent på i stort sett alla importerade varor. Men läkemedel undantas, enligt det senaste budet. Branschorganisationer betonar vik...

Double up for Korbinian Löbmann

This year, Korbinian Löbmann will moderate the New Updates in Drug Formulation & Bioavailability meeting in Copenhagen for the fifth time. Furthermore, he will ...

Europeiska läkemedelsaktier faller inför Trumps tullbesked

Flera bolag inom den europeiska läkemedelssektorn sjunker på börsen inför kvällens tullbesked från USA.

Ny behandling för Skelleftesjukan EU-godkänd

Svenska Purpose Pharma har fått sitt läkemedel Attrogy EU-godkänt som behandling av ärftlig transtyretinamyloidos, även kallat Skelleftesjukan.

Miljardsatsning ska få forskare att lämna USA för EU

Vita husets krav på ökat inflytande över universiteten har väckt oro för hotad akademisk frihet. Nu ska en ny EU-förorning locka amerikanska forskare till Europa, meddelar EU-kommissionens ordförande Ursula von der Leyen....

New diagnostic rules raise concerns

In a panel discussion, several voices from academia and the industry expressed concerns about the transition to the new regulatory framework for in-vitro diagno...

Första läkemedlet mot förlossningsdepression får grönt ljus i EU

EU-kommissionen har för första gången godkänt ett läkemedel mot förlossningsdepression, närmare bestämt amerikanska Biogens Zurzuvae.

Roche’s Genentech terminates licencing deal with Norwegian biotech

Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2025)

Astra Zeneca’s Sweden CEO: “We have great faith in our portfolio”

Sweden, which employs 7800 people in Södertälje, Stockholm and Gothenburg. “It was a very special feeling to be in charge of the entire organisation,” he says i...

Rapid developments in AI – “All stakeholders are struggling to understand it”

Artificial intelligence is being discussed more and more, and developments in the field are moving rapidly. As the Swedish Medical Products Agency testifies, ke...

New large lab building in Lund inaugurated – here are the companies moving in

Medicon Village has received a new laboratory building. On Friday last week the building was inaugurated with a ribbon-cutting ceremony by Minister for Employme...

Trump förnyar tullhot mot läkemedel

Hotet om amerikanska tullar på läkemedel tycks bli alltmer konkret. President Donald Trump nämner nu ”25 procent och högre” som en möjlig nivå.

600 million SEK for life science - "Should not be the country of moderation"

Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.

GU Ventures AB

Stockholm and Uppsala jointly form a life science cluster

Stockholm and Uppsala are strengthening cooperation in medical research and biotech.

ZEISS Lightfield 4D for instant volumetric high-speed imaging

Capturing physiological and neuronal processes in 3D.

Cantargia rekryterar ny medicinsk chef

Bioteknikbolaget Cantargia har utsett Wolfram Dempke till ny Chief Medical Officer (CMO). Han tillträder rollen omedelbart och efterträder Morten Lind Jensen, s...

Norway rejects national life science strategy – sees no need

The Norwegian Arbeiderpartiet rejects a proposal that Norway should develop its own life science strategy.

ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment

Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care.

Explore our tailored program for Control 2025

Choose an innovation tour, or join our industry-specific guided tours.

Beta-blockers are often given unnecessarily, a study finds – “This will affect future practice”

Patients who have suffered a minor heart attack do not benefit from beta-blockers, according to a major new study that may change guidelines for cardiac care.